Results from TiGenix's phase III Admire-CD trial for Cx601, a perianal fistulas treatment for Crohn's disease patients, were published in Gastroenterology.
Here's what you should know:
1. TiGenix conducted a 52-week trial finding Cx601 was statistically superior to a control drug in treating perianal fistulas in adults with non-active/mildly active luminal Crohn's disease.
2. The company views the publication as further validation of the drug's success.
3. TiGenix Vice President of Medical Affairs and Commercialization Mary Carmen Diez, MD, said, "We had previously announced the topline results from our 52-week analysis. These data showed a sustained effect of Cx601 treatment and supported our Marketing Authorization Application in Europe. We are pleased to see the full results published in such a prestigious journal, emphasizing the quality of the [trial] and the strength of the data supporting the development of Cx601."